Richard A Feelders Selected Research

Carcinoid Tumor (Carcinoid)

11/2022	Peptide Receptor Radionuclide Therapy.
1/2021	Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
1/2020	Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells.
8/2017	Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours.
7/2016	Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?
4/2008	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
1/2005	Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard A Feelders Research Topics

Disease

52	Neoplasms (Cancer) 10/2023 - 04/2005
34	Cushing Syndrome 03/2024 - 01/2003
24	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2023 - 01/2006
14	Adrenocortical Carcinoma 07/2023 - 11/2006
12	Adenoma (Adenomas) 01/2023 - 01/2003
11	Pituitary Neoplasms (Pituitary Adenoma) 03/2024 - 11/2006
11	Neoplasm Metastasis (Metastasis) 01/2023 - 01/2005
11	Pituitary ACTH Hypersecretion 01/2023 - 01/2010
8	ACTH-Secreting Pituitary Adenoma 01/2023 - 08/2005
8	Acromegaly 01/2023 - 07/2005
7	Carcinoid Tumor (Carcinoid) 11/2022 - 01/2005
6	Pheochromocytoma 11/2022 - 04/2008
6	Hyperplasia 05/2017 - 01/2003
5	Insulinoma 10/2023 - 09/2011
5	Paraganglioma (Paragangliomas) 11/2022 - 10/2006
5	Fibrosis (Cirrhosis) 04/2022 - 01/2017
4	Rheumatoid Arthritis 10/2013 - 01/2010
3	Gastrinoma 11/2022 - 01/2017
3	Vipoma (WDHA) 11/2022 - 04/2008
3	Thrombocytopenia (Thrombopenia) 07/2022 - 03/2010
3	Prolactinoma (Prolactinomas) 09/2021 - 09/2008
3	Diarrhea 01/2021 - 01/2017
3	Heart Failure 07/2019 - 05/2010
3	Primitive Neuroectodermal Tumors (PNET) 01/2019 - 08/2017
2	Glucagonoma 11/2022 - 01/2019
2	Growth Hormone-Secreting Pituitary Adenoma 09/2022 - 01/2017
2	Flushing 01/2021 - 01/2017
2	Hyperglycemia 01/2021 - 12/2013
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019 - 10/2006
2	Adrenal Cortex Neoplasms (Adrenocortical Cancer) 01/2019 - 01/2014
2	Polycythemia (Erythrocytosis) 01/2019 - 01/2017
2	Hypertension (High Blood Pressure) 01/2018 - 11/2011
2	Adrenocortical Adenoma (Disease, Conn's) 08/2014 - 02/2012

Drug/Important Bio-Agent (IBA)

28	Hydrocortisone (Cortisol)FDA LinkGeneric 03/2024 - 01/2003
25	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2023 - 04/2005
22	Somatostatin Receptors (Somatostatin Receptor)IBA 03/2024 - 04/2005
17	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2023 - 01/2003
11	Messenger RNA (mRNA)IBA 01/2023 - 01/2003
10	GlucocorticoidsIBA 03/2024 - 01/2010
8	Radioisotopes (Radionuclides)IBA 01/2023 - 04/2008
8	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2013
8	Peptide Receptors (Peptide Receptor)IBA 01/2023 - 01/2016
8	Cabergoline FDA LinkGeneric 01/2023 - 06/2008
7	Hormones (Hormone)IBA 10/2023 - 01/2003
7	lutetium Lu 177 dotatateIBA 01/2023 - 01/2019
7	Octreotide (Sandostatin)FDA LinkGeneric 01/2023 - 01/2005
6	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 10/2023 - 08/2004
6	Growth Hormone (Somatotropin)IBA 01/2023 - 11/2009
6	Dopamine Agonists (Dopamine Agonist)IBA 01/2023 - 09/2008
5	Dopamine (Intropin)FDA LinkGeneric 01/2023 - 06/2008
5	pasireotideIBA 01/2023 - 11/2009
5	Mitotane (Lysodren)FDA Link 03/2022 - 06/2013
5	Ketoconazole (Nizoral)FDA LinkGeneric 01/2021 - 05/2010
4	relacorilantIBA 10/2023 - 01/2021
4	Insulin-Like PeptidesIBA 07/2023 - 09/2011
4	OsilodrostatIBA 01/2023 - 01/2019
4	AlbuminsIBA 01/2023 - 11/2011
4	Serotonin (5 Hydroxytryptamine)IBA 04/2022 - 01/2017
4	SteroidsIBA 01/2022 - 05/2010
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 02/2012
3	LigandsIBA 03/2024 - 01/2023
3	CatecholaminesIBA 04/2022 - 09/2013
3	AcidsIBA 01/2021 - 01/2017
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2019 - 01/2018
3	177Lu-octreotateIBA 01/2016 - 04/2005
3	EnzymesIBA 09/2013 - 12/2007
3	Dopamine Receptors (Dopamine Receptor)IBA 02/2013 - 04/2007
2	Glucagon-Like Peptide-1 ReceptorIBA 10/2023 - 01/2015
2	Glucose (Dextrose)FDA LinkGeneric 10/2023 - 01/2021
2	ParaffinIBA 07/2023 - 09/2022
2	Formaldehyde (Formol)FDA Link 07/2023 - 09/2022
2	DNA (Deoxyribonucleic Acid)IBA 07/2023 - 01/2019
2	ProteomeIBA 01/2023 - 04/2022
2	Alkaline PhosphataseIBA 01/2023 - 07/2022
2	CorticosteroneIBA 01/2023 - 05/2010
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2022 - 01/2013
2	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2022 - 02/2010
2	SodiumIBA 06/2022 - 01/2018
2	Adrenergic Receptors (Adrenergic Receptor)IBA 04/2022 - 01/2020
2	LutetiumIBA 01/2021 - 01/2019
2	ArrestinsIBA 01/2020 - 05/2016
2	ArrestinIBA 01/2020 - 05/2016
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
2	Circulating Tumor DNAIBA 01/2019 - 10/2017
2	Metyrapone FDA Link 01/2019 - 11/2005
2	ErbB Receptors (EGF Receptor)IBA 01/2019 - 07/2013
2	MTOR InhibitorsIBA 01/2019 - 06/2012
2	Peptides (Polypeptides)IBA 01/2019 - 01/2018
2	Phosphopyruvate Hydratase (Enolase)IBA 07/2016 - 01/2016
2	Chromogranin AIBA 07/2016 - 01/2016
2	Sirolimus (Rapamycin)FDA Link 06/2016 - 08/2014
2	Everolimus FDA Link 12/2013 - 09/2011
2	Inhibins (Inhibin)IBA 09/2013 - 02/2012
2	InterferonsIBA 06/2013 - 11/2006
2	AldosteroneIBA 11/2011 - 05/2010
2	pegvisomant FDA LinkGeneric 09/2011 - 12/2007

Therapy/Procedure

33	Therapeutics 03/2024 - 01/2005
4	Adrenalectomy 12/2022 - 04/2012
4	Drug Therapy (Chemotherapy) 01/2021 - 06/2013
3	Radiotherapy 01/2016 - 01/2006